Portal de investigación
IBD CANCER AND SERIOUS INFECTIONS IN EUROPE: (I-CARE)./ EII CÁNCER E INFECCIONES GRAVES EN EUROPA: I-CARE.
Datos básicos
- Protocolo:
- GET-EII-2015-01
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2017
- Año de finalización:
- 2021
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A Nomogram Combining Fecal Calprotectin Levels and Plasma Cytokine Profiles for Individual Prediction of Postoperative Crohn's Disease Recurrence.
Cerrillo E; (...); Beltrán B
Article. 10.1093/ibd/izz053. 2019
A telemanagement system web in patients with complex inflammatory bowel disease: design and implementation of a randomized clinical trial
Meeting Abstract. 2017
A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.2196/11602. 2018
A web-based telemanagement system for patients with complex Inflammatory Bowel Disease (TECCU): Results of a randomised controlled clinical trial
Meeting Abstract. 2018
A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial
Aguas, Mariam; (...); Nos, Pilar
Article. 10.2196/resprot.9639. 2018
Accuracy of magnetic resonance enterography in the preoperative assessment of patients with Crohn's disease of the small bowel
Pous-Serrano, S; (...); Garcia-Granero, E
Article. 10.1111/codi.13613. 2017
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
Cañete F; (...); ENEIDA registry by GETECCU
Article. 10.1093/ibd/izz084. 2019
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial
Lopez-Sanroman, A; (...); Spanish GETECCU Grp APPRECIA Study
Article. 10.1093/ecco-jcc/jjx051. 2017
Adaptation of TECCU App Based on Patients ' Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups
Del Hoyo, J; (...); Aguas, M
Article. 10.3390/ijerph17061871. 2020
Adaptation of TECCU App based on patients' perceptions for telemonitoring inflammatory bowel disease: A qualitative study using focus groups
Francisco, JD; (...); Aguas, M
Meeting Abstract. 2020
Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU
Ballester Ferre, M. P.; (...); Minguez, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.727. 2021
Adsorptive granulocyte/monocyte apheresis use in severe ulcerative colitis and determination of changes in plasma cytokines
Beltran, B; (...); Nos, P
Article. 10.1002/jca.21552. 2018
Alpha-defensins (alpha-Defs) in Crohn's disease: decrease of ileal alpha-Def 5 via permanent methylation and increase in plasma alpha-Def 1-3 concentrations offering biomarker utility
Cerrillo, E; (...); Beltran, B
Article. 10.1111/cei.13085. 2018
Anti-TNFs patterns of use in clinical practice in inflammatory bowel disease (VERNE study)
Bastida, G; (...); Barreiro-de Acosta, M
Meeting Abstract. 10.1093/ecco-jcc/jjy222.251. 2019
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
Canete, F; (...); Domenech, E
Article. 10.14309/ctg.0000000000000218. 2020
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Chaparro, M; (...); EXIT Study Grp GETECCU
Article. 10.1177/1756284819874202. 2019
Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study
Panes, Julian; (...); Marin-Jimenez, Ignacio
Article. 10.1111/jgh.13795. 2017
Bases for the Adequate Development of Nutritional Recommendations for Patients with Inflammatory Bowel Disease
SÁEZ, E.; (...); BELTRÁN, B.
Article. 10.3390/nu11051062. 2019
Certification of integral care IBD Units: Evaluation of a certification program (CUE)
Barreiro-de Acosta, M; (...); GETECCU
Meeting Abstract. 2020
Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study.
Guerra I; (...); Gisbert JP
Article. 10.1093/ecco-jcc/jjz094. 2019
Colorectal cancer diagnosis in patients with inflammatory bowel disease in Spain: A room for improvement
Saldana, R; (...); Mateu, PN
Meeting Abstract. 2020
Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-alpha drug failure
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1016/j.dld.2018.01.124. 2018
Correlation between fecal calprotectin and inflammation in the surgical specimen of Crohn's disease
Pous-Serrano, Salvador; (...); Nos, Pilar
Article. 10.1016/j.jss.2017.02.064. 2017
Corrigendum to “Recomendaciones del Grupo Español de Trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento” [Gastroenterología y Hepatología 2020;43(10):649-658].
Barreiro-de Acosta M; (...); Nos P
Correction. 10.1016/j.gastrohep.2021.02.001. 2021
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; (...); Guerra I
Article. 10.1093/ibd/izab242. 2021
Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
Del Hoyo J, Aguas M
Letter. 10.1016/j.cgh.2020.06.016. 2021
Crohn's disease and self-monitoring through a mobile App: The Medicrohn study
Echarri, A; (...); Nos, P
Meeting Abstract. 2018
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?
Del Hoyo, Javier; (...); Aguas, Mariam
Article. 10.1016/j.gastrohep.2021.08.006. 2021
Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?
Del Hoyo Francisco, J.; (...); Aguas, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.758. 2021
Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M; (...); Domènech E
Article. 10.1111/jgh.15084. 2020
Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study
Cabre, E; (...); Domenech, E
Article. 10.1016/j.dld.2018.12.004. 2019
Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn's disease
Ladron Abia, P.; (...); Iborra, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.537. 2021
Depression and anxiety symptoms among patients with early inflammatory bowel disease during and after COVID-19 lockdown
Sempere Robles, L.; (...); van-der Hofstadt, C.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.270. 2021
Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn's Disease
Iborra, M; (...); Beltran, B
Article. 10.1159/000493726. 2019
Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn's disease
Mateos, B; (...); Beltran, B
Meeting Abstract. 10.1093/ecco-jcc/jjy222.725. 2019
DNA methylation signatures associated with pathogenesis Crohn's disease-related genes
Tatay, IM; (...); Beltran, B
Meeting Abstract. 2019
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Taxonera, C; (...); SEGURTB study gro GETECCU
Article. 10.1093/ecco-jcc/jjx022. 2017
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply
Editorial Material. 10.1111/apt.15447. 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
Casanova MJ; (...); Gisbert JP
Article. 10.1093/ibd/izz192. 2020
Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from Eneida Registry
Chaparro, M; (...); Esteve M
Meeting Abstract. 10.1093/ecco-jcc/jjz203.563. 2020
Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.
Chaparro, Maria; (...); Lázaro Pérez-Calle, José
Article. 10.1093/ecco-jcc/jjab070. 2021
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Article. 10.1007/s00535-016-1274-1. 2017
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients (vol 52, pg 788, 2017)
Iborra, M; (...); Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU).
Correction. 10.1007/s00535-016-1293-y. 2017
Effects of telemonitoring on safety and health care costs with a web platform (TECCU) in complex IBD patients: A randomised controlled trial
Meeting Abstract. 2018
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
Chaparro M; (...); Gisbert JP
Article. 10.1177/1756284819847034. 2019
Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Grp
Meeting Abstract. 10.1093/ecco-jcc/jjy222.914. 2019
Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2020
Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Grp
Meeting Abstract. 2018
Evolution of the emotional impact in patients with early inflammatory bowel disease during and after Covid-19 lockdown.
Sempere L; (...); Hofstadt CV
Article. 10.1016/j.gastrohep.2021.03.004. 2021
Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry.
Algaba A; (...); Bermejo F
Article. 10.1007/s10620-020-06424-x. 2020
Faecal calprotectin and plasma cytokines in the prediction of early postoperative Crohn's disease recurrence
Cerrillo, E; (...); Beltran, B
Meeting Abstract. 2018
Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease
Beltran, B; (...); Nos, P
Article. 10.1159/000492626. 2019
Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
Ladrón Abia P; (...); Bastida Paz G
Letter. 10.1016/j.gastrohep.2020.07.020. 2021
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease.
Chaparro M; (...); Gisbert JP
Article. 10.1177/1756284819867848. 2019
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease.
Aterido, A; (...); Julia, A
Article. 10.1038/s41397-019-0090-4. 2019
Granulocyte-monocyte apheresis combination therapy after loss of response to anti-TNF drugs
Rodriguez-Lago, I; (...); Cabriada, JL
Meeting Abstract. 2018
Identification of Epigenetic Methylation Signatures With Clinical Value in Crohn's Disease.
Moret-Tatay I; (...); Beltrán B
Article. 10.14309/ctg.0000000000000083. 2019
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study
de Paredes, AGG; (...); Lopez-Sanroman, A
Article. 10.1016/j.pan.2020.02.007. 2020
Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease
Saez-Gonzalez, Esteban; (...); Beltran, Belen
Review. 10.1007/s10620-017-4577-z. 2017
Impact of comorbidities on anti-TNF alpha response and relapse in patients with inflammatory bowel disease: the VERNE study
Marin-Jimenez, I; (...); Barreiro-de Acosta, M
Article. 10.1136/bmjgast-2019-000351. 2020
Impact of co-morbidities on loss and lack of response to anti-TNFs in inflammatory bowel disease: VERNE study
Marin-Jimenez, I; (...); Barreiro-de Acosta, M
Meeting Abstract. 10.1093/ecco-jcc/jjy222.433. 2019
Implementing telemedicine in inflammatory bowel disease: Is COVID-19 the definitive trigger?
Del Hoyo, J, Aguas, M
Editorial Material. 10.1016/j.gastrohep.2020.05.002. 2020
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
Chaparro, Maria; (...); Gisbert, Javier P.
Article. 10.3390/jcm10132885. 2021
Increased risk of thiopurine-related adverse events in elderly patients with IBD
Calafat, M; (...); ENEIDA Registry GETECCU
Article. 10.1111/apt.15458. 2019
Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience
Barreiro-de Acosta, M; (...); Nos, P
Article. 10.1002/ueg2.12105. 2021
Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
Bastida, G; (...); Nos, P
Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019
Influence of Vitamin D Deficiency on Inflammatory Markers and Clinical Disease Activity in IBD Patients
Lopez-Munoz, P; (...); Iborra, M
Article. 10.3390/nu11051059. 2019
Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?
Pérez de Arce E; (...); Nos P
Article. 10.1016/j.gastrohep.2021.02.022. 2021
Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry
Calafat, M; (...); ENEIDA Registry GETECCU
Meeting Abstract. 10.1093/ecco-jcc/jjy222.548. 2019
Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study
Ordás I; (...); Esteve M
Article. 10.1038/ajg.2017.180. 2017
Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
Chaparro, M; (...); Gisbert, JP
Article. 10.1038/ajg.2017.501. 2018
Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey
Rodriguez-Lago, I; (...); Gisbert, JP
Article. 10.1016/j.gastrohep.2018.09.002. 2019
Noninvasive Testing for Mucosal Inflammation in Inflammatory Bowel Disease.
Article. 10.1016/j.giec.2016.06.005. 2016
Oxidative Stress in the Pathogenesis of Crohn's Disease and the Interconnection with Immunological Response, Microbiota, External Environmental Factors, and Epigenetics
Alemany-Cosme, E; (...); Beltran, B
Review. 10.3390/antiox10010064. 2021
Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study
Manosa, M; (...); Geteccu
Article. 10.1111/apt.14494. 2018
Plasma Oncostatin M, TNF-a, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
Mateos B; (...); Beltrán B
Article. 10.1159/000508069. 2020
Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study
Ibanez-Sanz, Gemma; (...); Moreno, Victor
Article. 10.1038/s41598-018-20349-6. 2018
Primary prevention of post-operative recurrence of Crohn's disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
Canete, F; (...); Domenech, E
Meeting Abstract. 2018
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain
Hernandez Camba, A.; (...); Barreiro, M.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.312. 2021
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.
Hernandez Camba, Alejandro; (...); Barreiro-de Acosta, Manuel
Article. 10.1016/j.gastrohep.2021.08.007. 2021
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Taxonera, C; (...); Nos, P
Article. 10.1016/j.dld.2019.01.002. 2019
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients.
Article. 10.1038/s41598-020-73577-0. 2020
Real-life experience with long-term maintenance of golimumab in ulcerative colitis patients
Meeting Abstract. 10.1093/ecco-jcc/jjy222.683. 2019
Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease.
Huguet, JM; (...); Paredes, JM
Article. 10.12998/wjcc.v9.i36.11285. 2021
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Article. 10.1111/apt.15958. 2020
Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2020
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry
Iborra, M; (...); Chaparro, M
Article. 10.1111/apt.15371. 2019
Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry
Meeting Abstract. 10.1093/ecco-jcc/jjy222.629. 2019
Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis
Gonzalez-Lama, Y; (...); Gomollon, F
Article. 10.1016/j.gastrohep.2020.01.005. 2020
Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease.
Boscá MM; (...); Hinojosa J
Review. 10.1016/j.gastrohep.2019.09.012. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis.
Barreiro-de Acosta M; (...); Nos P
Editorial Material. 10.1016/j.gastrohep.2019.08.001. 2019
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment.
Barreiro-de Acosta M; (...); Nos P
Article. 10.1016/j.gastrohep.2020.04.004. 2020
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease
Domènech E; (...); Mañosa M
Review. 10.1016/j.gastrohep.2017.05.005. 2017
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of tiopurines in inflammatory bowel disease
Berrnejo, F; (...); Lopez-Sanroman, A
Review. 10.1016/j.gastrohep.2017.11.007. 2018
Recommendations of the Valencian Society of Digestive Pathology for the use of telemedicine and non-contact consultations.
Jover, Rodrigo; (...); Nos, Pilar
Article. 10.1016/j.gastrohep.2021.04.009. 2022
Regression of a giant pseudopolyp in a patient with colonic Crohn's disease after therapy with infliximab.
Sánchez Melgarejo JF; (...); Nos P
Article. 10.17235/reed.2019.6252/2019. 2019
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
Bermejo F; (...); Guerra I
Article. 10.1093/ibd/izab015. 2021
Relevance of dynamic studies with magnetic resonance enterography in Crohn's disease.
Pous S; (...); Nos P
Article. 10.1016/j.gastrohep.2019.11.010. 2020
Reviewing the therapeutic role of budesonide in Crohn's disease
Lopez-Sanroman, A; (...); Domenech, E
Review. 10.1016/j.gastrohep.2018.05.013. 2018
Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.
Calafat M; (...); ENEIDA Study Group of GETECCU
Article. 10.1093/ecco-jcc/jjab213. 2021
Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 10.1093/ecco-jcc/jjy222.561. 2019
Secondary Haemophagocytic Syndrome and Overlapping Immune Reconstitution Syndrome: Life-Threatening Complications of Anti-TNF-alpha Treatment for Crohn's Disease
Saez-Gonzalez, E; (...); Beltran, B
Letter. 10.1038/s41395-018-0420-1. 2019
Secukinumab-induced ulcerative colitis: opening Pandora's box of immunity
Fernandez-de La Varg, M; (...); Paz, GB
Letter. 10.1016/j.gastrohep.2019.12.004. 2020
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
Taxonera, C; (...); CONVERT Study Grp GETECCU
Article. 10.1093/ecco-jcc/jjy104. 2018
Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
Aguas Peris M; (...); Nos, P
Article. 10.1097/MIB.0000000000001182. 2017
Serum adalimumab levels predict successful remission and safe de-intensification in inflammatory bowel disease patients in clinical practice
Meeting Abstract. 2017
Should professionals provide their patients with digital health training resources?
Piudo, AE; (...); Marcos, NM
Meeting Abstract. 2020
Skin injuries associated with biological therapy in inflammatory bowel disease: beyond psoriasis.
Mínguez Sabater A; (...); Bastida G
Article. 10.1016/j.gastrohep.2020.09.003. 2022
Specific plasma micro-RNA profiles for prediction of recurrence in Crohn's disease in pre-surgery and established recurrence scenarios
Moret, I; (...); Beltran, B
Meeting Abstract. 2020
Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications.
Moret-Tatay, Ines; (...); Beltran, Belen
Article. 10.14309/ctg.0000000000000416. 2021
Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factors
Meeting Abstract. 2018
Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment.
Article. 10.3390/nu13061770. 2021
Surgical and hospital admission in adults newly diagnosed with inflammatory bowel disease (IBD) in the biological era in Spain: Results of the nationwide EpidemIBD study of GETECCU
Chaparro, M; (...); EpidemIBD Group
Meeting Abstract. 2018
Survey of adherence to treatment in inflammatory bowel disease. ENADEII study.
Alonso-Abreu I; (...); Quintero-Carrión E
Article. 10.1016/j.gastrohep.2019.10.007. 2020
Survey of adherence to treatment in inflammatory bowel disease: ENADEII STUDY
Abreu, IA; (...); GETECCU
Meeting Abstract. 2019
Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry.
Calafat M; (...); Domènech E
Article. 10.1093/ecco-jcc/jjaa055. 2020
Telemedicine in the treatment of patients with inflammatory bowel disease
Review. 10.1016/j.gastrohep.2017.07.001. 2017
Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.
Del Hoyo J; (...); Aguas M
Article. 10.2196/15505. 2019
Terapia de rescate con ciclosporina oral tras el uso de ustekinumab en colitis ulcerosa resistente a múltiples tratamientos.
Abia PL; (...); Niclós BB
Letter. 10.1016/j.gastrohep.2021.04.012. 2021
The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry
Guasch, M; (...); Domenech, E
Meeting Abstract. 2018
The ENEIDA registry (Nationwide study on genetic and environmental determinants of inflammatory bowel disease) by GETECCU: Design, monitoring and functions.
Zabana Y; (...); Domènech E
Article. 10.1016/j.gastrohep.2020.05.007. 2020
The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study.
Echarri A; (...); Muñiz J
Article. 10.1089/tmj.2018.0264. 2020
The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case-control study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 2018
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M; (...); Gisbert JP
Article. 10.1093/ecco-jcc/jjaa145. 2021
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFalpha used for the treatment of IBD: Results from the VERNE study.
Bastida G; (...); Barreiro-de Acosta M
Article. 10.1016/j.dld.2021.06.005. 2021
Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
Bejar, S; (...); Mateu, PN
Meeting Abstract. 2020
Urine metabolome profiling of immune-mediated inflammatory diseases
Alonso, A; (...); IMID Consortium
Article. 10.1186/s12916-016-0681-8. 2016
Use of Magnetic Resonance Index of Activity (MaRIA) in the preoperative assessment of small bowel Crohn's disease.
Pous-Serrano, S; (...); Garcia-Granero, E
Article. 10.1016/j.ciresp.2019.06.018. 2019
Use of telemedicine in inflammatory bowel disease: a real monitoring option?
Editorial Material. 10.1080/17474124.2016.1200464. 2016
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
Chaparro, M; (...); Gisbert, JP
Article. 10.1097/MEG.0000000000001706. 2020
Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients
Mateos, B.; (...); Beltran, B.
Meeting Abstract. 10.1093/ecco-jcc/jjab076.697. 2021
Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients
Meeting Abstract. 2018
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
Article. 10.1016/j.gastrohep.2018.06.001. 2018
Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse
Article. 10.1007/s10620-018-5429-1. 2019